Stock Track | Myriad Genetics Plummets 9.29% Following Q3 Losses and Cautious 2025 Outlook

Stock Track11-04

Shares of Myriad Genetics (NASDAQ: MYGN) plummeted 9.29% in Tuesday's trading session, extending the downward trend that began in after-hours trading on Monday. The sharp decline comes in the wake of the company's disappointing third-quarter 2025 financial results and a cautious outlook for the full fiscal year.

For Q3 2025, Myriad Genetics reported revenue of $205.7 million, slightly surpassing analyst estimates of $205.2 million. However, the genetic testing company posted a substantial net loss of $27.4 million, equivalent to an earnings per share (EPS) of -$0.29. On an adjusted basis, the company broke even with $0 EPS, narrowly beating the expected -$0.01 per share. The quarter's operating loss stood at $23.3 million, despite a gross margin of 69.9%.

Adding to investor concerns, Myriad Genetics provided a cautious outlook for the full fiscal year 2025. The company expects annual revenue in the range of $818-828 million, with adjusted EPS projected between -$0.02 and $0.02. This guidance suggests the possibility of continued losses, which likely contributed to the significant sell-off. As the genetic testing market becomes increasingly competitive, Myriad Genetics' ability to achieve profitability remains a key focus for investors, leading to the substantial plunge in stock price during Tuesday's trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151568059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151568059","market":"sg","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Plummets 9.29% Following Q3 Losses and Cautious 2025 Outlook","media":"Stock Track","content":"<p>Shares of Myriad Genetics (NASDAQ: MYGN) plummeted 9.29% in Tuesday's trading session, extending the downward trend that began in after-hours trading on Monday. The sharp decline comes in the wake of the company's disappointing third-quarter 2025 financial results and a cautious outlook for the full fiscal year.</p>\n\n<p>For Q3 2025, Myriad Genetics reported revenue of $205.7 million, slightly surpassing analyst estimates of $205.2 million. However, the genetic testing company posted a substantial net loss of $27.4 million, equivalent to an earnings per share (EPS) of -$0.29. On an adjusted basis, the company broke even with $0 EPS, narrowly beating the expected -$0.01 per share. The quarter's operating loss stood at $23.3 million, despite a gross margin of 69.9%.</p>\n\n<p>Adding to investor concerns, Myriad Genetics provided a cautious outlook for the full fiscal year 2025. The company expects annual revenue in the range of $818-828 million, with adjusted EPS projected between -$0.02 and $0.02. This guidance suggests the possibility of continued losses, which likely contributed to the significant sell-off. As the genetic testing market becomes increasingly competitive, Myriad Genetics' ability to achieve profitability remains a key focus for investors, leading to the substantial plunge in stock price during Tuesday's trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Plummets 9.29% Following Q3 Losses and Cautious 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Plummets 9.29% Following Q3 Losses and Cautious 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Myriad Genetics (NASDAQ: MYGN) plummeted 9.29% in Tuesday's trading session, extending the downward trend that began in after-hours trading on Monday. The sharp decline comes in the wake of the company's disappointing third-quarter 2025 financial results and a cautious outlook for the full fiscal year.</p>\n\n<p>For Q3 2025, Myriad Genetics reported revenue of $205.7 million, slightly surpassing analyst estimates of $205.2 million. However, the genetic testing company posted a substantial net loss of $27.4 million, equivalent to an earnings per share (EPS) of -$0.29. On an adjusted basis, the company broke even with $0 EPS, narrowly beating the expected -$0.01 per share. The quarter's operating loss stood at $23.3 million, despite a gross margin of 69.9%.</p>\n\n<p>Adding to investor concerns, Myriad Genetics provided a cautious outlook for the full fiscal year 2025. The company expects annual revenue in the range of $818-828 million, with adjusted EPS projected between -$0.02 and $0.02. This guidance suggests the possibility of continued losses, which likely contributed to the significant sell-off. As the genetic testing market becomes increasingly competitive, Myriad Genetics' ability to achieve profitability remains a key focus for investors, leading to the substantial plunge in stock price during Tuesday's trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"","article_id":"1151568059","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151568059","pubTimestamp":1762267842,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Myriad Genetics (NASDAQ: MYGN) plummeted 9.29% in Tuesday's trading session, extending the downward trend that began in after-hours trading on Monday. The sharp decline comes in the wake of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"个股追踪|Myriad Genetics继第三季度亏损和谨慎的2025年展望后暴跌9.29%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Shares of Myriad Genetics (NASDAQ: MYGN) plummeted 9.29% in Tuesday's trading session, extending the downward trend that began in after-hours trading on Monday. The sharp decline comes in the wake of the company's disappointing third-quarter 2025 financial results and a cautious outlook for the full fiscal year.\nFor Q3 2025, Myriad Genetics reported revenue of $205.7 million, slightly surpassing analyst estimates of $205.2 million. However, the genetic testing company posted a substantial net loss of $27.4 million, equivalent to an earnings per share (EPS) of -$0.29. On an adjusted basis, the company broke even with $0 EPS, narrowly beating the expected -$0.01 per share. The quarter's operating loss stood at $23.3 million, despite a gross margin of 69.9%.\nAdding to investor concerns, Myriad Genetics provided a cautious outlook for the full fiscal year 2025. The company expects annual revenue in the range of $818-828 million, with adjusted EPS projected between -$0.02 and $0.02. This guidance suggests the possibility of continued losses, which likely contributed to the significant sell-off. As the genetic testing market becomes increasingly competitive, Myriad Genetics' ability to achieve profitability remains a key focus for investors, leading to the substantial plunge in stock price during Tuesday's trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151568059","isCrawlerRequest":true}